Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SUCRALOSE IMPURITY B CRS (0.5MG)

SUCRALOSE IMPURITY B CRS (0.5MG)

NA

DISCOVER
SUCRALOSE CRS (550 MG)

SUCRALOSE CRS (550 MG)

56038-13-2

DISCOVER
ONDANSETRON  IMPURITY A CRS (20 MG)

ONDANSETRON IMPURITY A CRS (20 MG)

153139-56-1

DISCOVER
ONDANSETRON  IMPURITY G CRS (15 MG)

ONDANSETRON IMPURITY G CRS (15 MG)

NA

DISCOVER
GINSENOSIDE RB1 CRS (30 MG)

GINSENOSIDE RB1 CRS (30 MG)

41753-43-9

DISCOVER
GABAPENTIN IMPURITY B CRS (20MG)

GABAPENTIN IMPURITY B CRS (20MG)

133481-09-1

DISCOVER
GABAPENTIN IMPURITY D CRS (20MG)

GABAPENTIN IMPURITY D CRS (20MG)

NA

DISCOVER
PHENOBARBITAL IMPURITY A CRS (15 MG)

PHENOBARBITAL IMPURITY A CRS (15 MG)

NA

DISCOVER
PHENOBARBITAL IMPURITY B CRS (15 MG)

PHENOBARBITAL IMPURITY B CRS (15 MG)

NA

DISCOVER
NICERGOLINE FOR SYSTEM SUITABILITY CRS (10 MG)

NICERGOLINE FOR SYSTEM SUITABILITY CRS (10 MG)

27848-84-6

DISCOVER
CARBON MONOXIDE - REFERENCE SPECTRUM (N/A)

CARBON MONOXIDE - REFERENCE SPECTRUM (N/A)

ND

DISCOVER
BETAXOLOL IMPURITY C CRS (5 MG)

BETAXOLOL IMPURITY C CRS (5 MG)

NA

DISCOVER